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In the early 1960s, when Werner Kalow first published on the
“heredity and the response to drugs” (Kalow W [1962] Phar-
macogenetics: Heredity and the Response to Drugs. W. B.
Saunders, Philadelphia), the term “pharmacogenetics” was
born. It took another 20 years to identify mutations that are
at the core of an individual’s response to a particular
drug—findings that coincided with the discovery of amultitude
of drug-metabolizing enzymes. This body of work, by the ed-
itors of the present volume and by other researchers, merged
clinical observations with basic science and led to our current
understanding of how mutations, such as SNPs, alter the func-
tion of a gene product and thereby moderate drug metabolism.
The sequencing of the human genome and the arrival of new
high-throughput technologies made it possible to analyze DNA
in an expansive, highly parallel way; today, we are able to
analyze multiple genes simultaneously, rather than one at a
time. The term “pharmacogenetics” no longer adequately de-
scribes such large-scale, often genomewide approaches, and,
logically, the use of the term “pharmacogenomics” clearly il-
lustrates this parallel analysis of many genes. However, despite
these differences, the terms are often used interchangeably. It
is important to note, though, that “pharmacogenomics” wid-
ened the meaning to include new abilities, such as the use of
genetic markers for association studies and the identification
of novel drug targets.
Kalow begins by illustrating the historical aspects of phar-
macogenetics through a description of his research regarding
a number of fatal outcomes of patients taking the local an-
esthetic procaine. His conclusions at that time set the stage for
the development of individualized, gene-dependent drug ther-
apy, which is described in detail in the ensuing chapters. Today,
“personalized medicine” continues to be driven by increasing
information and a continuous flow of new knowledge devel-
oped from efforts such as the Human Genome Project and the
identification of causes of disease and variability in drug
response.
Several chapters of Pharmacogenomics explore the current
status of pharmacogenetics and describe, in detail, allelic var-
iants of genes associated with interindividual variability in
drug uptake, transport, and metabolism. Classical, well-stud-
ied examples such as cytochrome P450 2D6 (CYP2D6; de-
scription of the poor-metabolizer phenotype based on the dis-
covery of polymorphic debrisoquine/sparteine metabolism) are
described, as well as more recent findings about the importance
of genetic variants in nuclear receptors (i.e. estrogen and reti-
noic acid receptors) and drug transporters (i.e. ABC trans-
porters and multidrug-resistance protein).
Unfortunately, another important class of molecules—ion
channels—is relegated to a small section within the chapter
on receptors. In addition, a table on hepatotoxicity and QT
prolongation as two of the most common reasons for with-
drawal of drugs from the marketplace appears earlier in the
book, making it somewhat out of context. QT prolongation
is caused by mutations in genes that control the flux of po-
tassium and sodium ions across the membrane of myocytes.
The numerous reports attesting to their great clinical impor-
tance and, in particular, the implication of the HERG gene as
a cause of severe adverse drug reactions call for a more in-
depth description of this class of genes.
The authors also address questions related to the presence
of genetic variations that confer interindividual differences in
drug response and whether these variations are limited to in-
dividuals, families, populations, or ethnic groups. Interestingly,
the definition of ethnicity is shifting from a limited focus on
appearance and geographical location to one using a more
scientific approach that considers genetic differences between
populations. This new approach is based on two major ob-
servations: first, how the frequency of a particular genetic var-
iant differs between populations; and second, how different
populations have dissimilar variants. A separate chapter ad-
dresses these interethnic differences in drug response and elab-
orates on these findings through the use of several relevant
examples.
Despite the ∼100,000 deaths each year, in the United States
alone, that can be attributed to adverse drug reactions, phar-
macogenetics has not yet made the transition from bench re-
search to clinical applications. Urs. A. Meyer, in his chapter
on pharmacogenetics from clinical viewpoints ascribes this to
a lack of prospective studies to evaluate the impact of genetic
information on drug therapy. In addition, the complexity of
the tools of the trade (summarized in a later chapter), combined
with a lack of education in this area on the part of both phy-
sicians and patients, is a likely contributor to the slow accep-
tance of pharmacogenetics in the clinic. Meyer further sum-
marizes the immediate impact of the genetic background on
phenotypes and elaborates on the clinical relevance of phar-
macogenetic traits and genetic polymorphisms. Clearly, the
message conveyed is that new technologies will open the door
to clinical applications for the prediction of interindividual
differences in drug efficacy and toxicity on the basis of genetic
factors.
Pharmacogenomics includes several chapters on the tools
used to tackle the challenges of pharmacogenetics and -gen-
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omics research. In addition, a chapter is dedicated to the field
of “proteomics,” looking beyond the genome into the dynam-
ics of functional genomics. Although the genome is, with ex-
ceptions, identical in each cell, the expression of individual
genes is characteristic for each cell type and developmental
stage, as well as other cellular differences. Tools to analyze
gene expression profiles (the “transcriptome”), such as DNA
microarrays, are becoming widely used and are already an
established part of the genomics toolbox. However, it has been
shown that differences found in protein profiles (the “pro-
teome”) cannot be explained by extrapolating mRNA profiles
to the protein level. Other events, such as posttranslational
modifications, must contribute to this difference. Because we
are most interested in cellular function, we want to know about
the form in which the enzyme in front of us appears. These
profiles then can provide valuable information on disease-spe-
cific proteins, candidate targets, lead-compound identification,
and drug toxicity studies. Techniques to identify protein pro-
files have been developed for quite some time but have only
recently matured to the point of being readily available and
more or less easy-to-use tools. The chapter summarizes these
novel techniques and provides an outlook on the commercial
side of proteomic tools.
Bioinformatics has quickly become a major component of
pharmacogenomics, providing the ability to design and analyze
complex experiments and also to manage the vast amount of
information collected in these studies. Pharmacogenomics
elaborates on two main areas of bioinformatics: the resources
available on the Internet and the use of applied bioinformatics.
The very nature of the Web’s open architecture and nearly
unlimited flexibility makes it an opportune platform to access
and exchange genomic and genetic information. The massive
databases maintained by public and private institutions pro-
vide a wide range of data-mining capabilities. In Pharmaco-
genomics, the authors list and describe the resources andmajor
databases available on the Web. Despite the difficulty of pro-
viding a comprehensive and up-to-date overview of these re-
sources, the authors have done so carefully and with enough
depth to provide a valuable guideline for navigating and min-
ing these online resources for relevant genetic and genomic
information.
In summary, Pharmacogenomics describes the principles of
the field and guides interested readers to the relevant sources
and original literature, without going into extraneous detail.
By touching on all of the important issues, the authors have
provided a well-written overview on the state of the art of
pharmacogenomics.
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